Logo image
Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer
Journal article   Peer reviewed

Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer

Giandomenico Roviello, Edoardo Francini, Armando Perrella, Letizia Laera, Maria Antonietta Mazzei, Susanna Guerrini, Franco Roviello, Daniele Marrelli and Roberto Petrioli
Cancer biology & therapy, Vol.16(4), pp.493-497
04/03/2015
DOI: 10.1080/15384047.2015.1017692
PMID: 25719413
url
https://doi.org/10.1080/15384047.2015.1017692View
Published (Version of record) Open Access

Abstract

Bevacizumab and Tamoxifen are valid therapeutic options for metastatic breast cancer (mBC) patients. In this report, we describe a 47 year old woman with mBC successfully treated with a maintenance therapy with Bevacizumab+Tamoxifen. A maintenance approach using 2 different drugs with different targets and mechanism of action, such as anti-angiogenic and anti-hormonal treatment is particularly intriguing because they affect different pathways involved in mBC progression. Further studies including a large number of patients are needed, in order to select women who could benefit from this maintenance approach.
Bedside to Bench Report

Details

Metrics

Logo image